MRNS News and Press, Marinus Pharmaceuticals Inc. From 03/05/24

2024-03-05 21:29:12 ET Start Time: 16:30 End Time: 17:36 Marinus Pharmaceuticals, Inc. (MRNS) Q4 2023 Earnings Conference Call March 05, 2024, 16:30 PM ET Company Participants Scott Braunstein - CEO and Chairman Christy Shafer - Chief Commercial Officer J...

2024-03-05 16:42:18 ET Gainers: Ebang International Holdings  ( EBON ) +17% . CrowdStrike Holdings ( CRWD ) +17% . Couchbase ( BASE ) +14% . SOPHiA GENETICS ( SOPH ) +6% . Expensify ( EXFY ) +5% . Losers: ODDITY Tech...

2024-03-05 16:05:56 ET More on Marinus Pharmaceuticals Marinus Pharmaceuticals: A Capital Raise Is On The Horizon Marinus Pharmaceuticals Q4 2023 Earnings Preview Marinus Pharmaceuticals sees FY23 U.S. ZTALMY revenue $19.5M-$19.7M Seeking Alpha’s Quant...

Phase 3 RAISE trial interim analysis enrollment target achieved with Data Monitoring Committee (DMC) review scheduled and topline results expected in first half of Q2 2024 Phase 3 TrustTSC trial approximately 85% enrolled with topline data now expected in first half of Q4 2024 ZTALMY &#...

Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 on March 5, 2024. T...

2024-01-22 08:31:49 ET More on DiaMedica Therapeutics Seeking Alpha’s Quant Rating on DiaMedica Therapeutics Historical earnings data for DiaMedica Therapeutics Financial information for DiaMedica Therapeutics For further details see: DiaMedica The...

2024-01-04 12:45:20 ET More on Marinus Pharmaceuticals Marinus Pharmaceuticals: A Capital Raise Is On The Horizon Marinus Pharmaceuticals, Inc. (MRNS) Q3 2023 Earnings Call Transcript Marinus slips despite guidance raise amid delay for key readout Marinus Pha...

ZTALMY ® (ganaxolone) Q4 2023 preliminary net product revenue of between $6.5 and $6.7 million; full year 2023 preliminary net product revenue of between $19.5 and $19.7 million Projected full year 2024 U.S. ZTALMY net product revenue of between $32 and $34 million Over 90% of pa...

2023-12-29 14:42:38 ET Summary Today, we revisit Marinus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for rare genetic epilepsies and seizure disorders. The company's main asset is an approved drug called ganaxol...